COX2 inhibitors for acquired brain injuries: Is the time ripe?

Critical Care Medicine

Volumn 38, Issue 2, 2010, Pages 723-724

  Strauss, Kenneth I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PARECOXIB; ROFECOXIB;

BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN WEIGHT; COGNITION; CONVALESCENCE; EDITORIAL; NEUROPROTECTION; NEWBORN HYPOXIA; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 74949118796     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181bc80b9     Document Type: Editorial

References (18)

1. Blom MA, van Twillert MG, de Vries SC, et al: NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E2. Brain Research 1997; 777:210-218
2. Minghetti L: Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910
3. Gopez JJ, Yue H, Vasudevan R, et al: Cycloox-ygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 2005; 56: 590-604
4. Liu D, Wu L, Breyer R, et al: Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 2005; 57: 758-761
5. McCullough L, Wu L, Haughey N, et al: Neu-roprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24:257-268
6. Manabe Y, Anrather J, Kawano T, et al: Pro-stanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 2004; 55:668-675
7. Candelario-Jalil E, Alvarez D, Castañeda JM, et al: The highly selective cyclooxygenase-2 inhibitor DFU is neuroprotective when given several hours after transient cerebral ischemia in gerbils. Brain Res 2002; 927:212-215
8. Candelario-Jalil E, Alvarez D, Merino N, et al: Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils. Neurosci Res 2003; 47:245-253
9. Candelario-Jalil E, Gonzá lez-Falcó n A, García-Cabrera M, et al: Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res 2004; 1007: 98-108
10. Yue H, Jansen SA, Strauss KI, et al: A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and ep-oxyeicosatrienoic acids in rat brain tissue. J Pharm Biomed Anal 2007; 43:1122-1134
11. Hampson AJ, Grimaldi M: 12-hydroxyeicosa-tetrenoate (12-HETE) attenuates AMPA receptor-mediated neurotoxicity: Evidence for a G-protein-coupled HETE receptor. J Neu-rosci 2002; 22:257-264
12. Node K, Huo YQ, Ruan XL, et al: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285:1276-1279
13. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofe-coxib in a colorectal adenoma chemopreven-tion trial. N Engl J Med 2005; 352:1092-1102
14. Drazen JM: COX-2 inhibitors-A lesson in unexpected problems. N Engl J Med 2005; 352:1131-1132
15. Hippisley-Cox J, Coupland C: Risk of myocar-dial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 2005; 330:1366
16. Juni P, Nartey L, Reichenbach S, et al: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004; 364: 2021-2029
17. Nussmeier NA, Whelton AA, Brown MT, et al: Complications of the COX-2 inhibitors pare-coxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091
18. Psaty BM, Furberg CD: COX-2 inhibitors-lessons in drug safety. N Engl J Med 2005; 352: 1133-1135